STING ADCs
In 2022 Ryvu and Exelixis signed an exclusive license agreement focused on the development of novel targeted therapies utilizing Ryvu’s STING (STimulator of INterferon Genes) technology.
Key highlights
The agreement expands Exelixis’ portfolio of biotherapeutics by combining Ryvu’s proprietary small molecule STING agonists and STING biology know-how with Exelixis’ network of expertise and resources in antibody engineering, antibody-drug conjugate (ADC) technologies, and proven history of developing and commercializing oncology therapeutics.
Platform Collaborations
program
indication
discovery
PRECLINICAL
PHASE I
PHASE II
partner
program
STING ADCs
indication
Oncology
discovery
PRECLINICAL
PHASE I
PHASE II
partner
Contact
FOR MEDICAL PROFFESIONALS & INVESTIGATORS
If you are a medical professional, an investigator for a RYVU trial, or would like information about becoming an investigator, please contact us at [email protected] or use contact form.
